Cullin-RING ligases as attractive anti-cancer targets

Current Pharmaceutical Design

Volumn 19, Issue 18, 2013, Pages 3215-3225

  Zhao, Yongchao ^a   Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anticancer targets; Autophagy; CRL SCF E3 ligase; Cullins; MLN4924; NEDD8; Neddylation; Protein degradation; Ubiquitin; UPS

Indexed keywords

CULLIN; CULLIN RING LIGASE; CULLIN RING LIGASE 1; CULLIN RING LIGASE 2; CULLIN RING LIGASE 3; CULLIN RING LIGASE 4A; CULLIN RING LIGASE 4B; CULLIN RING LIGASE 5; CULLIN RING LIGASE 7; CULLIN RING LIGASE 9; ENZYME; F BOX PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGASE; NEDD8 PROTEIN; PEVONEDISTAT; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CELL HYPOXIA; CELL PROLIFERATION; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; NEDDYLATION; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITIN PROTEASOME SYSTEM; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CULLIN PROTEINS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEASOME INHIBITORS; PYRAZINES; UBIQUITIN-PROTEIN LIGASES;

EID: 84874995996     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990300     Document Type: Review

References (144)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu RevBiochem 1998; 67: 425-79.
2. Ciechanover A. The ubiquitin-proteasome pathway: on proteindeath and cell life. EMBO J 1998; 17: 7151-60.
3. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cellsignaling. Mol Cell 2009; 33: 275-86.
4. Deng L, Wang C, Spencer E, et al. Activation of the IkappaBkinase complex by TRAF6 requires a dimeric ubiquitinconjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-61.
5. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat CellBiol 2005; 7: 758-65.
6. Pickart CM. Ubiquitin in chains. Trends Biochem Sci 2000; 25:544-8.
7. Spence J, Sadis S, Haas AL, Finley D. A ubiquitin mutant withspecific defects in DNA repair and multiubiquitination. Mol Cell Biol 1995; 15: 1265-73.
8. Xu P, Duong DM, Seyfried NT, et al. Quantitative proteomicsreveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009; 137: 133-45.
9. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78: 399-434.
10. Michelle C, Vourc'h P, Mignon L, Andres C. What Was the Set ofUbiquitin and Ubiquitin-Like Conjugating Enzymes in the Eukaryote Common Ancestor? J Mol Evol 2009; 68: 616-28.
11. Markson G, Kiel C, Hyde R, et al. Analysis of the human E2ubiquitin conjugating enzyme protein interaction network. Genome Res 2009; 19: 1905-11.
12. Groettrup M, Pelzer C, Schmidtke G, Hofmann K. Activating theubiquitin family: UBA6 challenges the field. Trends Biochem Sci 2008; 33: 230-7.
13. Ye Y, Rape M. Building ubiquitin chains: E2 enzymes at work. NatRev Mol Cell Biol 2009; 10: 755-764.
14. Pickart CM. Ubiquitin enters the new millennium. Mol Cell 2001;8: 499-504.
15. Aravind L, Koonin EV. The U box is a modified RING finger acommon domain in ubiquitination. Curr Biol 2000; 10: R132-4.
16. Yu H. Cdc20: a WD40 activator for a cell cycle degradationmachine. Mol Cell 2007; 27: 3-16.
17. van Leuken R, Clijsters L, Wolthuis R. To cell cycle, swing theAPC/C. Biochim Biophys Acta 2008; 1786: 49-59.
18. Lipkowitz S, Weissman AM. RINGs of good and evil: RING fingerubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 2011; 11: 629-43.
19. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapiddegradation of p53. Nature 1997; 387: 296-9.
20. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stabilityby Mdm2. Nature 1997; 387: 299-303.
21. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. CancerBiol Therapy 2003; 2: 623-9.
22. Willems AR, Schwab M, Tyers M. A hitchhiker's guide to thecullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta 2004; 1695: 133-70.
23. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor ofNEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-6.
24. Zheng N, Schulman BA, Song LZ, et al. Structure of the Cul1-Rbx1-Skp1-F box(Skp2) SCF ubiquitin ligase complex. Nature 2002; 416: 703-9.
25. Jin J, Cardozo T, Lovering RC, et al. Systematic analysis andnomenclature of mammalian F-box proteins. Genes Dev 2004; 18: 2573-80.
26. Linossi EM, Nicholson SE. The SOCS box-adapting proteins forubiquitination and proteasomal degradation. IUBMB Life 2012; 64: 316-23.
27. Stogios PJ, Downs GS, Jauhal JJ, Nandra SK, Prive GG. Sequenceand structural analysis of BTB domain proteins. Genome Biol 2005; 6: R82.
28. He YJ, McCall CM, Hu J, Zeng Y, Xiong Y. DDB1 functions as alinker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev 2006; 20: 2949-54.
29. Sarikas A, Hartmann T, Pan ZQ. The cullin protein family. Genome Biol 2011; 12: 220.
30. Wu K, Fuchs SY, Chen A, et al. The SCFHOS/beta-TRCP-ROC1E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Molecular and Cellular Biology 2000; 20: 1382-93.
31. Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K. Nedd8 on cullin:building an expressway to protein destruction. Oncogene 2004; 23: 1985-97.
32. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15: 435-67.
33. Jia L, Sun Y. SCF E3 ubiquitin ligases as anticancer targets. CurrCancer Drug Targets 2011; 11: 347-56.
34. Skaar JR, Pagano M. Control of cell growth by the SCF and APC/Cubiquitin ligases. Curr Opin Cell Biol 2009; 21: 816-24.
35. Frescas D, Pagano M. Deregulated proteolysis by the F-boxproteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-49.
36. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumoursuppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
37. Strohmaier H, Spruck CH, Kaiser P, et al. Human F-box proteinhCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413: 316-22.
38. Yada M, Hatakeyama S, Kamura T, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23: 2116-25.
39. Welcker M, Orian A, Jin J, et al. The Fbw7 tumor suppressorregulates glycogen synthase kinase 3 phosphorylation-dependent cMyc protein degradation. Proc Natl Acad Sci USA 2004; 101: 9085-90.
40. Skaar JR, D'Angiolella V, Pagan JK, Pagano M. SnapShot: F BoxProteins II. Cell 2009; 137: 1358+1361.
41. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP.Skp2 regulates Myc protein stability and activity. Mol Cell 2003; 11: 1177-88.
42. von der Lehr N, Johansson S, Wu S, et al. The F-box protein Skp2participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003; 11: 1189-200.
43. Yeh KH, Kondo T, Zheng J, et al. The F-box protein SKP2 bindsto the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E. Biochem Biophys Res Commun 2001; 281: 884-90.
44. Tan M, Zhao Y, Kim SJ, et al. SAG/RBX2/ROC2 E3 UbiquitinLigase Is Essential for Vascular and Neural Development by Targeting NF1 for Degradation. Dev Cell 2011; 21: 1062-76.
45. Yan Y, Zhang X, Legerski RJ. Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27. Cell Cycle 2011; 10: 4098-109.
46. Inuzuka H, Shaik S, Onoyama I, et al. SCF(FBW7) regulatescellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-9.
47. Dehan E, Bassermann F, Guardavaccaro D, et al. BetaTrCP-andRsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 2009; 33: 109-16.
48. Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR Inhibitor, Is aPhysiological Substrate of SCF TrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy. Molecular Cell 2011; 44: 304-316.
49. Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006; 8: 645-54.
50. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006; 5: 596-613.
51. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-8.
52. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha tothe von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
53. Safran M, Kaelin WG, Jr.: HIF hydroxylation and the mammalianoxygen-sensing pathway. J Clin Invest 2003; 111: 779-83.
54. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor,hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003; 13: 83-9.
55. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
56. Xie L, Xiao K, Whalen EJ, et al. Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal 2009; 2: ra33.
57. Okuda H, Saitoh K, Hirai S, et al. The von Hippel-Lindau tumorsuppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem 2001; 276: 43611-7.
58. Na X, Duan HO, Messing EM, et al. Identification of the RNApolymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J 2003; 22: 4249-59.
59. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004; 24: 8477-86.
60. Venugopal R, Jaiswal AK. Nrf2 and Nrf1 in association with Junproteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998; 17: 3145-56.
61. Li W, Kong AN. Molecular mechanisms of Nrf2-mediatedantioxidant response. Mol Carcinog 2009; 48: 91-104.
62. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006; 3: e420.
63. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanentactivation of an adaptive response in cancer. Trends Biochem Sci 2009; 34: 176-88.
64. Hernandez-Munoz I, Lund AH, van der Stoop P, et al. Stable Xchromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci USA 2005; 102: 7635-40.
65. Kwon JE, La M, Oh KH, et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J Biol Chem 2006; 281: 12664-72.
66. Higa LA, Mihaylov IS, Banks DP, Zheng J, Zhang H. Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol 2003; 5: 1008-15.
67. Jin J, Arias EE, Chen J, Harper JW, Walter JC. A family of diverseCul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 2006; 23: 709-21.
68. Sugasawa K, Okuda Y, Saijo M, et al. UV-induced ubiquitylationof XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 2005; 121: 387-400.
69. Abbas T, Shibata E, Park J, et al. CRL4(Cdt2) regulates cellproliferation and histone gene expression by targeting PR-Set7/Set8 for degradation. Mol Cell 2010; 40: 9-21.
70. Nakagawa T, Xiong Y. X-linked mental retardation gene CUL4Btargets ubiquitylation of H3K4 methyltransferase component WDR5 and regulates neuronal gene expression. Mol Cell 2011; 43: 381-91.
71. Lee J, Zhou P. Cullins and cancer. Genes Cancer 2010; 1: 690-9.
72. Wei D, Sun Y. Small RING finger proteins RBX1 and RBX2 ofSCF E3 ubiquitin ligases: the role in cancer and as cancer targets. Genes & Cancer 2010; 1: 700-7.
73. Schindl M, Gnant M, Schoppmann SF, Horvat R, Birner P. Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res 2007; 27: 949-52.
74. Liu L, Yin Y, Li Y, Prevedel L, Lacy EH, Ma L, Zhou P. Essentialrole of the CUL4B ubiquitin ligase in extra-embryonic tissue development during mouse embryogenesis. Cell Research 2012.
75. Zhao Y, Sun Y. CUL4B ubiquitin ligase in mouse development: Amodel for human X-linked mental retardation syndrome? Cell Res 2012; 22: 1224-6.
76. Tarpey PS, Raymond FL, O'Meara S, et al. Mutations in CUL4B,Which Encodes a Ubiquitin E3 Ligase Subunit, Cause an X-linked Mental Retardation Syndrome Associated with Aggressive Outbursts, Seizures, Relative Macrocephaly, Central Obesity, Hypogonadism, Pes Cavus, and Tremor. The American Journal of Human Genetics 2007; 80: 345-52.
77. Zou Y, Liu Q, Chen B, et al. Mutation in CUL4B, which encodes amember of cullin-RING ubiquitin ligase complex, causes X-linked mental retardation. Am J Hum Genet 2007; 80: 561-6.
78. Laszlo GS, Cooper JA. Restriction of Src activity by Cullin-5. CurrBiol 2009; 19: 157-62.
79. Pan Q, Qiao F, Gao C, et al. Cdk5 targets active Src for ubiquitin-dependent degradation by phosphorylating Src(S75). Cell Mol Life Sci 2011; 68: 3425-36.
80. Yu X, Yu Y, Liu B, et al. Induction of APOBEC3G ubiquitinationand degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302: 1056-60.
81. Querido E, Blanchette P, Yan Q, et al. Degradation of p53 byadenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 2001; 15: 3104-17.
82. Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. EC5Subiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2006; 2: e116.
83. Xu X, Sarikas A, Dias-Santagata DC, et al. The CUL7 E3 ubiquitinligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell 2008; 30: 403-14.
84. Huber C, Dias-Santagata D, Glaser A, et al. Identification ofmutations in CUL7 in 3-M syndrome. Nat Genet 2005; 37: 1119-24.
85. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle controland cancer. Nat Rev Cancer 2006; 6: 369-81.
86. Petroski MD, Deshaies RJ. Function and regulation of cullin-RINGubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20.
87. Huang Y, Duan H, Sun Y. Elevated expression ofSAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but its antisense transfection inhibits tumor cell growth. Mol Carcinog 2001; 30: 62-70.
88. Jia L, Soengas MS, Sun Y. ROC1/RBX1 E3 ubiquitin ligasesilencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res 2009; 69: 4974-82.
89. Jia L, Yang J, Hao X, et al. Validation of SAG/RBX2/ROC2 E3Ubiquitin Ligase as an Anticancer and Radiosensitizing Target. Clin Cancer Res 2010; 16: 814-24.
90. Yang D, Li L, Liu H, et al. Induction of autophagy and senescenceby knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. Cell Death Differ 2012.
91. Jia L, Bickel JS, Wu J, et al. RBX1 (RING-box protein 1) E3ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins. J Biol Chem 2011; 286: 3379-86.
92. Mendez J, Zou-Yang XH, Kim SY, et al. Human origin recognitioncomplex large subunit is degraded by ubiquitin-mediated proteolysis after initiation of DNA replication. Mol Cell 2002; 9: 481-91.
93. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is anmTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-86.
94. Gao D, Inuzuka H, Tan M, Kwang M, et al. mTOR Drives Its OwnActivation via SCF TrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR. Molecular Cell 2011; 44: 290-303.
95. Duan S, Skaar Jeffrey R, Kuchay S, et al. mTOR Generates anAuto-Amplification Loop by Triggering the TrCP-and CK1 -Dependent Degradation of DEPTOR. Molecular Cell 2011; 44: 317-24.
96. Tan M, Gallegos JR, Gu Q, et al. SAG/ROC-SCFbeta-TrCP E3ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. Neoplasia 2006; 8: 1042-54.
97. Tan M, Zhu Y, Kovacev J, et al. Disruption of Sag/Rbx2/Roc2induces radiosensitization by increasing ROS levels and blocking NF-kB activation in mouse embryonic stem cells. Free Radic Biol Med 2010; 49 976-83.
98. Gu Q, Bowden GT, Normolle D, Sun Y. SAG/ROC2 E3 ligaseregulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB. J Cell Biol 2007; 178: 1009-23.
99. He H, Gu Q, Zheng M, Normolle D, Sun Y. SAG/ROC2/RBX2 E3ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27. Carcinogenesis 2008; 29: 858-65.
100. Duda DM, Borg LA, Scott DC, et al. Structural insights intoNEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008; 134: 995-1006.
101. Deshaies RJ, Emberley ED, Saha A. Control of cullin-RINGubiquitin ligase activity by Nedd8. In: Conjugation and Deconjugation of Ubiquitin Family Modifiers: Subcellular Biochemistry. 54. Groettrup M (Ed) (2010):41-56.
102. Rabut G, Peter M. Function and regulation of protein neddylation.'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9: 969-76.
103. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE. TheNEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer 2010; 1: 708-16.
104. Kamura T, Conrad MN, Yan Q, Conaway RC, Conaway JW. TheRbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 1999; 13: 2928-33.
105. Goldenberg SJ, Cascio TC, Shumway SD, et al. Structure of theCand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 2004; 119: 517-28.
106. Yamoah K, Oashi T, Sarikas A, et al. Autoinhibitory regulation ofSCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc Natl Acad Sci USA 2008; 105: 12230-5.
107. Liu J, Furukawa M, Matsumoto T, Xiong Y. NEDD8 modificationof CUL1 dissociates p120(CAND1), an inhibitor of CUL1-SKP1 binding and SCF ligases. Mol Cell 2002; 10: 1511-8.
108. Zheng J, Yang X, Harrell JM, et al. CAND1 binds to unneddylatedCUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell 2002; 10: 1519-26.
109. Saha A, Deshaies RJ. Multimodal activation of the ubiquitin ligaseSCF by Nedd8 conjugation. Mol Cell 2008; 32: 21-31.
110. Lyapina S, Cope G, Shevchenko A, et al. Promotion of NEDD8-CUL1 Conjugate Cleavage by COP9 Signalosome. Science 2001; 292: 1382-5.
111. Lo S-C, Hannink M. CAND1-Mediated Substrate AdaptorRecycling Is Required for Efficient Repression of Nrf2 by Keap1. Molecular and Cellular Biology 2006; 26: 1235-44.
112. Bjorklund M, Taipale M, Varjosalo M, et al. Identification ofpathways regulating cell size and cell-cycle progression by RNAi. Nature 2006; 439: 1009-13.
113. Bech-Otschir D, Seeger M, Dubiel W. The COP9 signalosome: atthe interface between signal transduction and ubiquitin-dependent proteolysis. Journal of Cell Science 2002; 115: 467-73.
114. Wei N, Serino G, Deng XW. The COP9 signalosome: more than aprotease. Trends in Biochemical Sciences 2008; 33: 592-600.
115. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assistedinhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010; 37: 102-11.
116. Milhollen MA, Traore T, Adams-Duffy J, et al. MLN4924, aNEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010; 116: 1515-23.
117. Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796-800.
118. Tan M, Li Y, Yang R, Xi N, Sun Y. Inactivation of SAG E3Ubiquitin Ligase Blocks Embryonic Stem Cell Differentiation and Sensitizes Leukemia Cells to Retinoid Acid. PLoS One 2011; 6: e27726.
119. Milhollen MA, Narayanan U, Soucy TA, et al. Inhibition ofNEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011; 71: 3042-51.
120. Jia L, Li H, Sun Y. Induction of p21-Dependent Senescence by anNAE Inhibitor, MLN4924, as a Mechanism of Growth Suppression. Neoplasia 2011; 13: 561-9.
121. Lin HK, Chen Z, Wang G, et al. Skp2 targeting suppressestumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464: 374-9.
122. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010; 70: 10310-20.
123. Zhao Y, Xiong, X., Jia, L., and Sun, Y. Targeting cullin-RINGligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Disease 2012; 3: doi:10.1038/cddis.2012.1125.
124. Luo Z, Yu G, Lee HW, et al. The Nedd8-Activating EnzymeInhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth. Cancer Res 2012; 72: 3360-71.
125. Mizushima N, Yoshimori T, Levine B. Methods in mammalianautophagy research. Cell 2010; 140: 313-26.
126. Zhao Y, Sun Y. Targeting the mTOR-DEPTOR Pathway by CRLE3 Ubiquitin Ligases: Therapeutic Application. Neoplasia 2012; 14: 360-7.
127. Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with theSKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 1998; 95: 11324-29.
128. Abbas T, Sivaprasad U, Terai K, et al. PCNA-dependent regulationof p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev 2008; 22: 2496-506.
129. Kim Y, Starostina NG, Kipreos ET. The CRL4Cdt2 ubiquitinligase targets the degradation of p21Cip1 to control replication licensing. Genes Dev 2008; 22: 2507-19.
130. Winston JT, Strack P, Beer-Romero P, et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and betacatenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999; 13: 270-83.
131. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy:lessons from the first decade. Clin Cancer Res 2008; 14: 1649-57.
132. Wei D, Li H, Yu J, et al. Radiosensitization of human pancreaticcancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 2012; 72: 282-93.
133. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009; 15: 3912-6.
134. Xirodimas DP. Novel substrates and functions for the ubiquitin-likemolecule NEDD8. Biochem Soc Trans 2008; 36: 802-6.
135. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004; 118: 83-97.
136. Milhollen MA, Thomas MP, Narayanan U, et al. Treatment-Emergent Mutations in NAEbeta Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924. Cancer Cell 2012; 21: 388-401.
137. Toth JI, Yang L, Dahl R, Petroski MD. A gatekeeper residue for NEDD8-activating enzyme inhibition of MLN4924. Cell Reports 2012; 1: 309-16.
138. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-6.
139. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes andcore pathways. Nature 2008; 455: 1061-8.
140. Yang Y, Kitagaki J, Dai RM, et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancertherapeutics. Cancer Res 2007; 67: 9472-81.
141. Ceccarelli DF, Tang X, Pelletier B, et al. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell 2011; 145:1075-87.
142. Aghajan M, Jonai N, Flick K, et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCFfamily E3 ubiquitin ligase. Nat Biotechnol 2010; 28: 738-42.
143. Chen Q, Xie W, Kuhn DJ, et al. Targeting the p27 E3 ligaseSCF(Skp2) results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008; 111: 4690-9.
144. Orlicky S, Tang X, Neduva V, et al. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol 2010; 28: 733-7.